Biosergen AS
The answer first
Does Biosergen beat the market?
No, Biosergen has not beaten the market over the last year.
Max for seven days
Follow Biosergen with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 22 October 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Biosergen
Your first answer is free, no account needed.
Do you own Biosergen, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Biosergen and a few more. Free, no card.
Super Stock+47.8%In short
- Biosergen has fallen 99.0% over the past year, including dividends.
- The largest fall over the past three years was 99.5%. The price is 99.9% below its peak now.
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
- Debt to equityBorrowings divided by equity4.29
- Asset turnoverSales divided by everything the company owns0.00
- Return on equityProfit divided by equity−347.0%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
- P/BPrice divided by equity1.6
- P/SPrice divided by sales82.0
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
- 3 months−92.4%
- 6 months−95.0%
- 9 months−98.8%
- 12 months−99.0%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
About Biosergen
Biosergen AS is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 1 employees.
Biosergen AB (publ), a biotech company, develops antifungal drugs. Its lead product is BSG005, an antifungal drug candidate for the treatment of invasive fungal infections in immunocompromised patients, including AIDS, cancer, and transplant recipients. The company was founded in 2004 and is based in Solna, Sweden.


See the full analysis of Biosergen.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card